Abeona Therapeutics Inc
ABEO
Company Profile
Business description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
136
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
stocks
Bookworm: Is this the secret to exceptional long-term returns?
Acceptance may be an investor’s best friend.
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,934.30 | 45.10 | -0.50% |
CAC 40 | 7,834.58 | 16.30 | 0.21% |
DAX 40 | 24,217.50 | 78.43 | -0.32% |
Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
FTSE 100 | 9,120.31 | 18.06 | -0.20% |
HKSE | 25,388.35 | 278.83 | -1.09% |
NASDAQ | 21,108.32 | 50.36 | 0.24% |
Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
S&P 500 | 6,388.64 | 25.29 | 0.40% |
S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
SSE Composite Index | 3,593.66 | 12.07 | -0.33% |